Abstract 33P
Background
The circulating predictive factors for survival of advanced non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs) remain elusive. We aimed to identify the predictive value of circulating cytokines and programmed cell death ligand-1 (PD-L1) expression for survival.
Methods
Serum samples from 102 advanced-stage NSCLC patients who underwent immunotherapy were collected at baseline. PD-L1 expression was also analyzed.
Results
Positive PD-L1 expression (≥1%) was detected in 49.0% of patients. Compared with PD-L1-negative patients, PD-L1-positive patients had a significantly higher ORR (70% vs. 28.8%, p<0.05) and an increased mPFS (25.35 vs. 4.64 months, p=0.003), and tended to have increased mOS (44.84 vs. 20.42 months, p=0.087). CXCL12 levels in the top 33% (1/3) was a poor prognostic factor for durable clinical benefit (DCB, 23.5% vs. 72.1%, p<0.001), PFS (3.76 vs. 14.4 months; p<0.001) and OS (12.2 vs. 44.84 months; p=0.008), and a signature comprising PD-L1<1% and top 33% CXCL12 was associated with lowest ORR (27.3% vs. 73.7%, p<0.001), DCB (27.3% vs. 73.7%, p<0.001) and the worst mPFS (2.44 vs. 25.35 months, p<0.001) and mOS (11.97 vs. 44.84 months, p=0.007). Area under the curve (AUC) analysis for PD-L1 expression, CXCL12 level or PD-L1 expression plus CXCL12 level to predict DCB or NDB showed AUC value as 0.680, 0.719 and 0.794 respectively.
Conclusions
Our findings suggest that the combination of circulating cytokine CXCL12 level and PD-L1 status can predict survival of advanced NSCLC patients treated with ICIs.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.